American Journal of Kidney Diseases
Volume 52, Issue 6, Supplement 1 , Pages S14-S20 , December 2008

A Comprehensive Vision for Intravenous Iron Therapy

  • Daniel W. Coyne, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Daniel W. Coyne, MD, Washington University School of Medicine, 600 Euclid Ave, Campus Box 8129, St Louis, MO 63110

References 

  1. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–788
  2. Małyszko J, Małyszko JS, Hryszko T, Pawlak K, Mysliwiec M. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?. Am J Nephrol. 2005;25:586–590
  3. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093
  4. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(suppl 1):S4–S8
  5. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19:141–149
  6. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis. 2001;37(suppl 1):S182–S238
  7. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S11–S145
  8. Sunder-Plassmann G, Hörl WH. Erythropoietin and iron. Clin Nephrol. 1997;47:141–157
  9. Kopelman RC, Smith L, Peoples L, Biesecker R, Rizkala AR. Functional iron deficiency in hemodialysis patients with high ferritin. Hemodial Int. 2007;11:238–246
  10. Lin JL, Chang MY, Tan DT, Leu ML. Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol. 2001;21:91–97
  11. Tarng DC, Huang TP, Chen TW, Yang WC. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload. Kidney Int Suppl. 1999;69:S107–S118
  12. Aronoff GR. Safety of intravenous iron in clinical practice: Implications for anemia management protocols. J Am Soc Nephrol. 2004;15(suppl 2):S99–S106
  13. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol. 1996;7:2654–2657
  14. Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis. 1997;30:912–922
  15. Low CL, Bailie GR, Eisele G. Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients. Ren Fail. 1997;19:781–788
  16. Singh AK, Coyne DW, Shapiro W, Rizkala AR DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 2007;71:1163–1171
  17. Coyne DW, Kapoian T, Suki W, et al. DRIVE Study Group Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975–984
  18. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19:161–167
  19. Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis. 2001;38:109–117
  20. Centers for Medicare & Medicaid Services. 2006 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project. Bethesda, MD: Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards and Quality; 2007;
  21. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41–46
  22. Sepandj F, Jindal K, West M, Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant. 1996;11:319–322
  23. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995;10:2070–2076
  24. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1079–1083

 This article was published as part of a supplement sponsored by an educational grant from Watson Pharmaceuticals.

PII: S0272-6386(08)01315-2

doi: 10.1053/j.ajkd.2008.09.003

American Journal of Kidney Diseases
Volume 52, Issue 6, Supplement 1 , Pages S14-S20 , December 2008

Article Tools

* Image Usage & Resolution